Physician profile
Kelly Wright
NPI 1720479223
$5,181.48
in general payments reported to CMS, 2019-2025
33 companies · $1,752 in 2025
The $1,752 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.78 · 2022: $267 · 2023: $1,007 · 2024: $2,116 · 2025: $1,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,643 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,643.47 |
| Education | $231.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,800.27 | 2023-2025 | |
| Janssen Biotech, INC. | $756.61 | 2023-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $421.28 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $301.57 | 2023-2025 | |
| Novo Nordisk INC | $269.95 | 2021-2025 | Wegovy |
| Aimmune Therapeutics, INC. | $250.09 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $194.05 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $169.17 | 2023-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $124.62 | 2023-2024 | Ocaliva |
| Enterra Medical, INC. | $92.22 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.60 | 2024-2025 | Trulance, Relistor |
| Ardelyx, INC. | $76.60 | 2023-2025 | Ibsrela |
| Smith+Nephew, INC. | $66.60 | 2025 | Collagenase Santyl |
| Ipsen Biopharmaceuticals, INC | $64.74 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $50.97 | 2023-2025 | Omvoh |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.54 | 2023-2025 | |
| Qol Medical, LLC | $46.20 | 2025 | Sucraid |
| Genzyme Corporation | $35.69 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $32.18 | 2023 | |
| Celltrion USA INC. | $31.14 | 2024-2025 | Vegzelma, Zymfentra |
| Coloplast Corp | $30.89 | 2024 | |
| Braintree Laboratories, INC. | $26.92 | 2025 | Suflave, Sutab |
| Averitas Pharma INC. | $23.81 | 2024 | Qutenza |
| Astrazeneca Pharmaceuticals Lp | $23.72 | 2022 | |
| Aroa Biosurgery Incorporated | $21.12 | 2025 | |
| Madrigal Pharmaceuticals | $20.75 | 2025 | Rezdiffra |
| Mimedx Group, INC. | $19.35 | 2025 | |
| Organon LLC | $18.34 | 2023 | Hadlima |
| Convatec INC. | $16.80 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.84 | 2021 | |
| Vivus LLC | $15.51 | 2024 | Qsymia |
| Ironwood Pharmaceuticals, INC | $14.82 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $13.52 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.